Is Hologic, Inc. (HOLX) a good stock to buy?

Olyth's institutional analysis of HOLX reveals an Altman Z-Score of 4.22 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($4.10B most recent), help investors decide if HOLX fits their risk profile.

What is the current P/E ratio for HOLX?

As of the latest trading session, Hologic, Inc. (HOLX) has a trailing P/E ratio of 31.36.

Who is the CEO of Hologic, Inc.?

The current Chief Executive Officer of Hologic, Inc. is Stephen MacMillan.

What was HOLX's revenue for the last 5 years?

According to its latest income statements, Hologic, Inc. reported annual revenues of $4.10B (2025), $4.03B (2024), $4.03B (2023), $4.86B (2022), $5.63B (2021) respectively.

Does HOLX pay a dividend?

Hologic, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does HOLX have?

In its latest reporting period, Hologic, Inc. generated $0.92B in Free Cash Flow against a total debt load of $2.63B.

What is the Price-to-Book (P/B) ratio of Hologic, Inc.?

The Price-to-Book (P/B) ratio for Hologic, Inc. (HOLX) is currently 3.25.

What is the Price-to-Sales (P/S) ratio of HOLX?

Based on trailing twelve-month data, Hologic, Inc. (HOLX) trades at a Price-to-Sales (P/S) ratio of 4.11.

What is Hologic, Inc.'s Return on Equity (ROE)?

Hologic, Inc. (HOLX) has a Return on Equity (ROE) of 11.01%, representing its profitability relative to shareholder equity.

HOLX

Hologic, Inc. · Healthcare

76.01

0.48%(+0.36)

Prev. Close

76.50

0.64%(+0.49)

Pre-market

Last Updated: — ET

52W L: $51.9052W H: $76.07

$76.04

CHG+0.33 (+0.44%)

H$76.10

L$74.96

VOL138M

HOLX (1h)

Company Profile

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

7,063

IPO Date

1990-03-01

Beta

0.70

Websitewww.hologic.com↗

HOLX

Hologic Target of Unusually Large Options Trading (NASDAQ:HOLX)

Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

Exchange Traded Concepts LLC Lowers Position in Hologic, Inc. $HOLX

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Hologic (NASDAQ:HOLX) Hits New 52-Week High – Time to Buy?